Build status - In Progress

CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) (CATHY)

CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) (CATHY)
Recruiting
18 years - 99 years
All
Phase 3
11 participants needed
1 Location

Brief description of study

The study compares two acute graft-versus-host disease (aGVHD) prophylaxis regimens: CD24Fc/tacrolimus / methotrexate (CD24Fc/Tac/MTX) versus placebo/tacrolimus / methotrexate (placebo/Tac/MTX) in the setting of myeloablative conditioning (MAC), matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation in participants with acute leukemia (AML/ALL) or myelodysplastic syndrome (MDS).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hematopoietic Stem Cell Transplantation,Acute Graft Versus Host Disease,Acute Myeloid Leukemia,Acute Lymphoblastic Leukemia,Myelodysplastic Syndromes,
  • Age: 18 years - 99 years
  • Gender: All

Male and Female, Age 18 or older, A prospective participant for allogeneic HCT for a malignant hematologic disorder.

Updated on 04 Aug 2024. Study ID: 843884

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center